RCUS 241018 17.50C (RCUS241018C17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

RCUS241018C17500

Watchlist

0.76
-0.44-36.67%

15min DelayClose Oct 16 16:00 ET

0.92High0.76Low

Intraday

5D
Daily

News

BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Cuts Target Price to $22
Moomoo NewsOct 15 05:34 ET · Ratings
Balanced Outlook: Hold Rating on Arcus Biosciences Amid Pipeline Challenges and Market Uncertainty
TipRanksOct 15 05:06 ET · Ratings
Arcus Biosciences Announces New Employment Inducement Grants
BusinesswireOct 9 16:35 ET
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
InvestingOct 9 12:03 ET
Are Investors Undervaluing Arcus Biosciences, Inc. (NYSE:RCUS) By 23%?
Simply Wall StOct 9 08:23 ET
Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price
Yahoo FinanceOct 9 08:09 ET

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Moomoo AI

Mar 22 05:31

The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.

Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding

Moomoo AI

Feb 23 04:42

Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.

Optimistic Investors Push Arcus Biosciences, Inc. (NYSE:RCUS) Shares Up 27% But Growth Is Lacking

Moomoo AI

Feb 13 04:49

Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation